

Understand a company's history and their drug portfolio

Cortellis Competitive Intelligence


This guide explains how to use company reports in Cortellis to evaluate company's activities, drug portfolio and expertise.

When analyzing companies for partnering opportunities, you need to evaluate their recent activities and their drug pipeline to assess if they are a suitable match for your company. You also need to identify:

- Top indications they are focusing on.
- Number of drugs they have in the market, as well as clinical trials and preclinical.
- Any merger or acquisition they've been part of in the past.

Example: Analyze a company's history and drug portfolio e.g. Akcea Therapeutics Inc based in the US.

1. Type the company name at the top and click 'Index' search.
2. Make sure 'Companies' is selected under 'Report type' on the left and click company name from the results table.



The screenshot shows the Cortellis search interface. At the top, the search term 'akcea' is entered in the search bar, and the 'Index' search button is highlighted with a purple box. Below the search bar, the results are displayed in a table. The 'Report Type' sidebar on the left has 'Companies (3)' selected. The table shows three results for 'akcea':

Report Type	Results	Parent Company Name	Organization Type	Key Technologies	Field of Activity	Country
Companies (3)	Akcea Therapeutics Inc	Ionis Pharmaceuticals Inc	Organization Sub-Type : Company	Antibody fragment; Antibody; Imaging; Immunodetection; Monoclonal antibody; Peptide; Transgenic mouse	Biologics	US
	Akcea Therapeutics UK Ltd	Ionis Pharmaceuticals Inc				UK
	Ionis Pharmaceuticals Inc	Ionis Pharmaceuticals Inc	Organization Sub-Type : Company Company Type : Public Company Size : Medium	Biological therapeutic; Oligonucleotide antisense; Subcutaneous formulation; Parenteral formulation unspecified; RNA antisense;	Pharmaceuticals	US

A purple box highlights the 'Parent Company Name' column for the first result, with a text box explaining: 'Parent Company Name' -2nd column- indicates if the company of interest is part of a larger organization. In this case, Akcea Therapeutics Inc. is a subsidiary of Ionis Pharmaceutical Inc.

- Select 'Company Profile' tab from the menu on the left to read the history of the company. Company profiles are overviews written and manually curated by Cortellis editors summarizing information on mergers, acquisitions, spin offs and comments on financial data.

Company Report

Akcea Therapeutics Inc

Snapshot Highlight Search Terms & Synonyms < Previous Next >

Latest Press Releases COMPANY PROFILE

Latest Event Transcripts SUMMARY

Broker Research Reports Akcea Therapeutics Inc is an affiliate of [Isis Pharmaceuticals](#) which is focused on the development and commercialization of the drugs in Isis' lipid franchise.

Company Profile ACQUISITIONS AND SPIN-OFFS

In October 2020, Ionis Pharmaceuticals announced the successful completion of its transaction to acquire 100% ownership of Akcea Therapeutics [[2339467](#)].

Funding In August 2020, Ionis signed an agreement with the company to acquire all Akcea's shares that it did not already own, approximately 24%, for \$18.15 per share in cash. The transaction was expected to close in the fourth quarter of 2020 [[2312894](#)]. In October 2020, Ionis completes acquisition of Akcea [[2339467](#)].

Financials In September 2017, the company and Ionis (formerly Isis) established a wholly owned Canadian subsidiary, Akcea Therapeutics Canada Inc [[1959548](#)].

Company Contacts LICENSING AGREEMENTS

Subsidiary Companies In August 2020, Ionis Pharmaceuticals and its affiliate Akcea Therapeutics entered into a definitive agreement under which Ionis acquired all of the outstanding shares of Akcea common stock that was not already own, approximately 24%, for \$18.15 per share in cash [[2312894](#)].

Drug Sales and Forecasts FINANCIAL

Drugs In July 2017, the company announced the pricing of its initial public offering of 15,625,000 shares of common stock at a public offering price of \$8 per share, for gross proceeds of \$125 million. At that time, Akcea had granted the underwriters a 30-day option to buy up to 2,343,750 additional shares of common stock at the public offering price, less underwriting discount and commissions, to cover over-allotments, if any. Akcea's shares were expected to begin trading on the NASDAQ Global Select Market on July 14, 2017 under the symbol "AKCA." The offering was expected to close on July 19, 2017, subject to customary closing conditions. In addition, [Novartis Pharma](#) had agreed to purchase \$50 million of Akcea's common stock in a separate private placement concurrent with the completion of Akcea's initial public offering at a price per share equal to the initial public offering price. The closing of the initial public offering was not conditioned upon the closing of the concurrent private placement [[1945079](#)]; later that month, the initial public offering of 17,968,750 shares common stock at a public offering was closed. The gross proceeds from the offering were \$143.8 million. Novartis Pharma purchased \$50.0 million of Akcea's common stock in a separate private placement. Akcea's common stock was listed on the NASDAQ Global Select Market under the symbol "AKCA" [[1946414](#)].

Deals In March 2017, the company filed a registration statement on Form S-1 with the SEC, for the proposed public offering of its common stock. At that time, the company applied to list its common stock on the Nasdaq Global Market under the trading symbol "AKCA" for 9,620,000 shares of common stock and the underwriters would have a 30-day option expected to be between \$12.00 and \$14.00 per share [[1939029](#)].

Clinical Trials

Patents

Change History

Sources

Paragraphs in company profiles start with month/year followed by the update/news and source of the information at the end.

Click blue links to see the source of information.

- Go to the 'Drugs' tab to find an interactive and integrated chart providing number of drugs developed by Akcea by indication allowing you to identify areas with highest activities in R&D.

Akcea Therapeutics Inc

Snapshot Highlight Search Terms & Synonyms < Previous Next >

Latest Press Releases DRUGS

Latest Event Transcripts

Broker Research Reports

Company Profile

Funding

Financials

Company Contacts

Subsidiary Companies

Drug Sales and Forecasts

Drugs

By Indication

By Highest Status

Drugs by Indication

Active Drugs by Indication

View

Launched
Phase 3 Clinical
Phase 2 Clinical
Preclinical

Indications

Rare disease

Cardiovascular disease

Neurological disease

Metabolic disorder

Neurological disease

Number of Drugs


0 1 2 3 4

Neurological disease
Launched 1
Phase 3 Clinical 1
Total 2

'Active drugs' are those in discovery, preclinical, clinical phases, preregistered, registered, suspended or launched.

Hover over one of the bars to display number of drugs per phase for each indication.

- A second chart in the same tab displays the company's drug pipeline allowing you to identify whether they are focused on early research or drugs in late stage as well as evaluate companies to identify the best business partners for future deals, acquisitions or mergers.



- Deals, clinical trials and patent landscape are tabulated in separate tabs to facilitate analysis of these activities.

Akcea Therapeutics Inc

Snapshot Highlight Search Terms & Synonyms < Previous Next >

	DEALS					
	Agreement Type	Target (Principal Company)		Acquirer (Partner Company)		Total
		Active	Inactive	Active	Inactive	
Latest Press Releases						
Latest Event Transcripts						
Broker Research Reports						
Company Profile	Drug - Development/Commercialization License	1	0	1	0	2
Funding	Drug - Manufacturing/Supply	0	0	2	0	2
Financials	Drug - Commercialization License	1	0	0	0	1
Company Contacts	Drug - Funding	1	0	0	0	1
Subsidiary Companies	Technology - Other Proprietary	0	0	1	0	1
Drug Sales and Forecasts	View deals as a results list					
Drugs						
Deals						
Agreement Type						
Asset & Transaction Type						
Clinical Trials						
Patents						
	Deal Asset Type	Principal		Partner		Total
		Active	Inactive	Active	Inactive	
	+ Product	5	0	7	0	12
	Capital(Grants/Loans/Equity Inv./ Royalty buyouts)	1	0	0	0	1
	+ Service	0	0	1	0	1

To find out what's included in your subscription, contact your Clarivate account manager or **[LS Product Support](#)**